Promising Results for Depression Treatment with Microdosing LSD

August 27, 2024 Lynne Nardizzi

MindBio Therapeutics Corp. (CSE) has recently unveiled promising durability data from its Phase 2A clinical trials, which tested MB22001, the company’s innovative self-administered, take-home microdose of Lysergic Acid Diethylamide (LSD), as a treatment for depression.

This development underscores MindBio’s commitment to advancing psychedelic medicine as a viable option for mental health treatment.

Resources for Post-Psychedelic Difficulties

August 16, 2024 Lynne Nardizzi

Shared from Ecstatic Integration.

If you’re dealing with post-psychedelic difficulties, here are some resources:

Fireside Project is a phone support service for people experiencing psychedelic or post-psychedelic difficulties.

ICEERS is a plant medicine NGO which has a free support centre.

A university clinic in Berlin which provides free consultations on post-psychedelic difficulties

Cheetah House also offers consultations on post-psychedelic and post-meditation adverse experiences.

The Challenging Psychedelic Experiences Project offers a free online support group for post-psychedelic difficulties on the last Sunday of every month (next one August 25th). We also have research on post-psychedelic difficulties and what helps people cope with them, including a new paper on post-psychedelic existential confusion and ontological shock.

Three Studies of MDMA Treatment Retracted by Scientific Journal

August 15, 2024 Lynne Nardizzi

The journal Psychopharmacology has retracted three papers about MDMA-assisted therapy based on what the publication said was unethical conduct at one of the study sites where the research took place.

Several of the papers’ authors are affiliated with Lykos Therapeutics, the drug company whose application for MDMA-assisted therapy to treat post-traumatic stress disorder was rejected last week by the Food and Drug Administration.

MDMA- Legal and Ethical Concerns

August 14, 2024 Lynne Nardizzi

The FDA did not approve MDMA, here’s a breakdown of the legal and ethical concerns.

Psilocybin for Alcohol Addiction Treatment

August 13, 2024 Lynne Nardizzi

A groundbreaking study has recently highlighted that psilocybin, a naturally occurring psychedelic compound found in some hallucinogenic mushrooms, can significantly reduce alcohol consumption in rats.

This discovery could pave the way for novel treatments for alcohol addiction.

FDA rejects MDMA-Assisted Therapy for PTSD

August 12, 2024 Lynne Nardizzi

Big news for MDMA-assisted therapy. Here are a couple takes on it:

https://themicrodose.substack.com/p/breaking-news-federal-regulators

https://psychedelicinvest.com/fda-denies-lykos-and-requests-another-trial/

Ketamine Clinics Expected to Explode Over the Next Five Years

August 6, 2024 Lynne Nardizzi

The U.S. Ketamine Clinic industry is growing fast.

This is because more people are looking for new ways to treat mental health problems. It’s already a $3.1B industry, but it’s expected to more than double over the next five years.